數位PCR(dPCR)和實時PCR(qPCR)市場規模,份額和趨勢分析:產品和服務,應用,最終用戶,區域前景,競爭戰略,按類別預測~2030
市場調查報告書
商品編碼
1072844

數位PCR(dPCR)和實時PCR(qPCR)市場規模,份額和趨勢分析:產品和服務,應用,最終用戶,區域前景,競爭戰略,按類別預測~2030

Digital PCR (dPCR) and Real-time PCR (qPCR) Market Size, Share & Trends Analysis By Product & service, By Application, By End-User, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030

出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球數位 PCR (dPCR) 和實時 PCR (qPCR) 市場在預測期內將保持 8.8% 的複合年增長率,預計到 2030 年將增長到 113.9 億美元。

先進的 PCR 技術、投資增加、遺傳和傳染病增加、生物標誌物分析在疾病診斷中的重要性增加以及蓬勃發展的人類基因組計劃等因素正在推動市場的增長。另一方面,qPCR 和 dPCR 技術的技術限制以及昂貴的相關設備等問題可能會阻礙市場擴張。

本報告調查了全球數位 PCR (dPCR) 和實時 PCR (qPCR) 市場,包括市場概況、對市場增長的各種影響因素分析、市場規模趨勢/預測以及各個類別/地區/細分按主要國家、主要公司概況等匯總。

目錄

第一章介紹

第二章調查方法

第 3 章執行摘要

第四章市場動態

  • 成長因素、制約因素、機會、問題分析
  • COVID-19 的影響

第 5 章市場變量/展望

  • SWOT分析
  • PESTEL 分析
  • 波特五力分析
  • 熱圖分析

第 6 章全球 dPCR 和 qPCR 市場:按產品和服務分類

  • qPCR 產品與服務
    • qPCR試劑和耗材
    • qPCR設備
    • qPCR軟件服務
  • dPCR 產品和服務
    • dPCR設備
    • dPCR 試劑和耗材
    • dPCR 軟件服務

第 7 章全球 dPCR 和 qPCR 市場:按應用分類

  • qPCR
    • 臨床
    • 法醫學
    • 研究
  • dPCR
    • 臨床
    • 研究
    • 法醫學

第 8 章全球 dPCR 和 qPCR 市場:按最終用戶分類

  • dPCR 最終用戶
    • 臨床研究所
    • 法醫實驗室
    • 醫院/診斷中心
    • 製藥和生物技術公司
    • 研究/學術機構
  • qPCR 最終用戶
    • 臨床研究所
    • 法醫實驗室
    • 醫院/診斷中心
    • 製藥和生物技術公司
    • 研究和學術機構

第 9 章全球 dPCR 和 qPCR 市場:按地區劃分

  • 北美
  • 歐洲
  • 亞太地區
  • 南美洲
  • 中東/非洲

第 10 章公司簡介

  • Abbott Laboratories
  • Agilent Technologies
  • Analytik Jena AG
  • Becton Dikinson and Company
  • bioMerieux SA
  • Bioneer
  • Bio-Rad Laboratories Inc.
  • Danaher Corporation
  • ELITech Group
  • Enzo Life Sciences, Inc.
  • Eppendorf
  • F. Hoffmann-La Roche, Ltd.
  • Fluidigm Corporation
  • Merck KGaA
  • Meridian Bioscience
  • Promega Corporation
  • QIAGEN N.V.
  • Quidel Corporation
  • Takara Bio
  • Thermo Fisher Scientific
簡介目錄
Product Code: BIOT2217

Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market projected to be worth USD 11.39 billion by 2030.

According to SPER Market Research, the Digital PCR (dPCR) and Real-time PCR (qPCR) Market estimated to reach USD 11.39 billion by 2030 with a CAGR of 8.8%.

The key fuels for the market escalation are; advanced PCR technologies, growing investments, increasing genetic as well as targeted infectious disease, raising the exploit of biomarkers profiling in the disease diagnosis, and the booming Human Genome project.

Impact of COVID-19 on the Digital PCR (dPCR) and Real-time PCR (qPCR) Market

The COVID-19 outbreak has mainly impacted to the healthcare industry; diagnostic industry is one of them. There is a positive impact in the PCR industries. Digital PCR (dPCR) and Real-time PCR (qPCR) has the importance in the diagnostic and drug discovery. The focus of the companies is to produce digital PCR kits for the diagnosis of the infection.

Scope of the report:

  • Market size available for years: 2019-2030
  • Base year considered: 2021
  • Forecast period: 2022-2030

Segments covered By Product & Service, By Application, By End-User, By Region.

Geographies covered: North America, Europe, Asia Pacific, Latin America, Middle East, Africa

Companies Covered: Abbott Laboratories, Agilent Technologies, Analytik Jena AG, Becton, Dikinson and Compan, bioMerieux SA, Bioneer, Bio-Rad Laboratories Inc.Dan, aher Corporation, ELITech Group, Enzo Life Sciences, Inc., Eppendorf, F. Hoffmann-La Roche, Ltd., Fluidigm Corporation, Merck KGaA, Meridian Bioscience, Promega Corporation, QIAGEN N.V., Quidel Corporation, Thermo Fisher Scientific, Takara Bio

Driver: growing occurrence of target infectious diseases and genetic disorders

Rising incidence of target infectious diseases and genetic disorders, technological advancements in PCR technologies, increasing investments, funds, and grants, increasing use of biomarker profiling for disease diagnostics, successful completion of the Human Genome Project; are the key drives of the escalation of the market.

Restraint: High device costs coupled with dPCR

Technical limitations of qPCR and dPCR techniques, costly device coupled with dPCR; can resist the escalation of the market.

Opportunity: rising market penetration in emerging countries

Growing market penetration in emerging countries, shift from plant-derived to genome-based drug discovery; offers enormous opportunities to the players in the market.

Challenges:

Adoption and implementation of MIQE guidelines, is the challenge to the market expansion.

Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market, By Product & Service:

Based on the Product and Service, Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market is segmended as; qPCR Products & Services (qPCR Reagents and Consumables, qPCR Instruments, qPCR Software and Services), dPCR Products & Services (dPCR Instruments, dPCR Reagents and Consumables, dPCR Software and Services).

Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market, By Application:

Based on the Application, Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market is segmended as; qPCR Applications (Clinical Applications, Forensic Applications, Research Applications), dPCR Applications (Clinical Applications, Research Applications, Forensic Applications).

Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market, By End-User:

Based on the End-User, Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market is segmended as; qPCR End User (Clinical Research Organizations, Forensic Laboratories, Hospitals and Diagnostic Centers, Pharmaceutical and Biotechnology Companies, Research Laboratories and Academic Institutes), qPCR End User (Clinical Research Organizations, Forensic Laboratories, Hospitals and Diagnostic Centers, Pharmaceutical and Biotechnology Companies, Research Laboratories and Academic Institutes).

Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market, By Region:

North America, dominates the principal share of this market; and this is because of accessibility to research & development funding, growing acceptance of innovative and novel genomic analysis, escalating use of PCR techniques in the clinical diagnostics, forensics, and commercialization of qPCR/dPCR products.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Digital PCR (dPCR) and Real-time PCR (qPCR) Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market, By Product & Service, 2019-2030 (USD Million)

  • 6.1. qPCR Products & Services
    • 6.1.1. qPCR Reagents and Consumables
    • 6.1.2. qPCR Instruments
    • 6.1.3. qPCR Software and Services
  • 6.2. dPCR Products & Services
    • 6.2.1. dPCR Instruments
    • 6.2.2. dPCR Reagents and Consumables
    • 6.2.3. dPCR Software and Services

7. Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market, By Application, 2019-2030 (USD Million)

  • 7.1. qPCR Applications
    • 7.1.1. Clinical Applications
    • 7.1.2. Forensic Applications
    • 7.1.3. Research Applications
  • 7.2. dPCR Applications
    • 7.2.1. Clinical Applications
    • 7.2.2. Research Applications
    • 7.2.3. Forensic Applications

8. Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market, By End-User, 2019-2030 (USD Million)

  • 8.1. dPCR End User
    • 8.1.1. Clinical Research Organizations
    • 8.1.2. Forensic Laboratories
    • 8.1.3. Hospitals and Diagnostic Centers
    • 8.1.4. Pharmaceutical and Biotechnology Companies
    • 8.1.5. Research Laboratories and Academic Institutes
  • 8.2. qPCR End User
    • 8.2.1. Clinical Research Organizations
    • 8.2.2. Forensic Laboratories
    • 8.2.3. Hospitals and Diagnostic Centers
    • 8.2.4. Pharmaceutical and Biotechnology Companies
    • 8.2.5. Research Laboratories and Academic Institutes

9. Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market, By Region, 2019-2030 (USD Million)

  • 9.1. North America
    • 9.1.1. United States
    • 9.1.2. Canada
    • 9.1.3. Mexico
  • 9.2. Europe
    • 9.2.1. Germany
    • 9.2.2. United Kingdom
    • 9.2.3. France
    • 9.2.4. Italy
    • 9.2.5. Spain
    • 9.2.6. Rest of Europe
  • 9.3. Asia-Pacific
    • 9.3.1. China
    • 9.3.2. Japan
    • 9.3.3. India
    • 9.3.4. Australia
    • 9.3.5. South Korea
    • 9.3.6. Rest of Asia-Pacific
  • 9.4. South America
  • 9.5. Middle East & Africa
    • 9.5.1. Kingdom of Saudi Arabia
    • 9.5.2. United Arab Emirates
    • 9.5.3. Rest of Middle East & Africa

10. Company Profiles

  • 10.1. Abbott Laboratories
    • 10.1.1. Company details
    • 10.1.2. Financial outlook
    • 10.1.3. Product summary
    • 10.1.4. Recent developments
  • 10.2. Agilent Technologies
    • 10.2.1. Company details
    • 10.2.2. Financial outlook
    • 10.2.3. Product summary
    • 10.2.4. Recent developments
  • 10.3. Analytik Jena AG
    • 10.3.1. Company details
    • 10.3.2. Financial outlook
    • 10.3.3. Product summary
    • 10.3.4. Recent developments
  • 10.4. Becton Dikinson and Company
    • 10.4.1. Company details
    • 10.4.2. Financial outlook
    • 10.4.3. Product summary
    • 10.4.4. Recent developments
  • 10.5. bioMerieux SA
    • 10.5.1. Company details
    • 10.5.2. Financial outlook
    • 10.5.3. Product summary
    • 10.5.4. Recent developments
  • 10.6. Bioneer
    • 10.6.1. Company details
    • 10.6.2. Financial outlook
    • 10.6.3. Product summary
    • 10.6.4. Recent developments
  • 10.7. Bio-Rad Laboratories Inc.
    • 10.7.1. Company details
    • 10.7.2. Financial outlook
    • 10.7.3. Product summary
    • 10.7.4. Recent developments
  • 10.8. Danaher Corporation
    • 10.8.1. Company details
    • 10.8.2. Financial outlook
    • 10.8.3. Product summary
    • 10.8.4. Recent developments
  • 10.9. ELITech Group
    • 10.9.1. Company details
    • 10.9.2. Financial outlook
    • 10.9.3. Product summary
    • 10.9.4. Recent developments
  • 10.10. Enzo Life Sciences, Inc.
    • 10.10.1. Company details
    • 10.10.2. Financial outlook
    • 10.10.3. Product summary
    • 10.10.4. Recent developments
  • 10.11. Eppendorf
    • 10.11.1. Company details
    • 10.11.2. Financial outlook
    • 10.11.3. Product summary
    • 10.11.4. Recent developments
  • 10.12. F. Hoffmann-La Roche, Ltd.
    • 10.12.1. Company details
    • 10.12.2. Financial outlook
    • 10.12.3. Product summary
    • 10.12.4. Recent developments
  • 10.13. Fluidigm Corporation
    • 10.13.1. Company details
    • 10.13.2. Financial outlook
    • 10.13.3. Product summary
    • 10.13.4. Recent developments
  • 10.14. Merck KGaA
    • 10.14.1. Company details
    • 10.14.2. Financial outlook
    • 10.14.3. Product summary
    • 10.14.4. Recent developments
  • 10.15. Meridian Bioscience
    • 10.15.1. Company details
    • 10.15.2. Financial outlook
    • 10.15.3. Product summary
    • 10.15.4. Recent developments
  • 10.16. Promega Corporation
    • 10.16.1. Company details
    • 10.16.2. Financial outlook
    • 10.16.3. Product summary
    • 10.16.4. Recent developments
  • 10.17. QIAGEN N.V.
    • 10.17.1. Company details
    • 10.17.2. Financial outlook
    • 10.17.3. Product summary
    • 10.17.4. Recent developments
  • 10.18. Quidel Corporation
    • 10.18.1. Company details
    • 10.18.2. Financial outlook
    • 10.18.3. Product summary
    • 10.18.4. Recent developments
  • 10.19. Takara Bio
    • 10.19.1. Company details
    • 10.19.2. Financial outlook
    • 10.19.3. Product summary
    • 10.19.4. Recent developments
  • 10.20. Thermo Fisher Scientific
    • 10.20.1. Company details
    • 10.20.2. Financial outlook
    • 10.20.3. Product summary
    • 10.20.4. Recent developments